Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2019 Nov 1;107(3):563–570. doi: 10.1002/cpt.1641

Table 3.

Percent of patients with neurotoxicity or elevated liver transaminases prescribed voriconazole per the CYP2C19-guided prophylaxis protocol

Neurotoxicity
CYP2C19 genotype Yes, No. (%) No, No. (%) P
 CYP2C19*1/*17 4 (8.7) 42 (91.3) 0.18
 CYP2C19*1/*1 14 (21.9) 50 (78.1)
 CYP2C19*2/*17 3 (18.7) 13 (81.3)
 CYP2C19*1/*2 3 (7.5) 37 (92.5)
 CYP2C19*2/*2 1 (14.3) 6 (85.7)
Elevated liver transaminases
CYP2C19 genotype Yes, No. (%) No, No. (%) P
 CYP2C19*1/*17 3 (6.5) 43 (93.5) 0.83
 CYP2C19*1/*1 7 (10.9) 57 (89.1)
 CYP2C19*2/*17 1 (6.3) 15 (93.7)
 CYP2C19*1/*2 3 (7.5) 37 (92.5)
 CYP2C19*2/*2 1 (14.3) 6 (85.7)